Please assess the completion status of the following clinical trial:

Trial Title: Topical DHEA Against Vaginal Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women (non hysterectomized or hysterectomized)~* Women between 40 and 75 years of age~* Willing to participate in the study and sign an informed consent~* Women having a low maturation index (no greater part of guidance than 5% of superficial cells on vaginal smear)~* Women having a vaginal pH above 5~* Women who have self-identified at least one moderate to severe symptoms of vulvovaginal atrophy~Exclusion Criteria:~* Undiagnosed abnormal genital bleeding~* Hypertension equal to or above 160/95 mm Hg or not controlled by standard therapy~* The administration of any investigational drug within 30 days of screening visit~* Endometrial hyperplasia at biopsy performed at screening or endometrial cancer~* Use of estrogens/progestins products (vaginal, oral, pellet, transdermal, etc) in the 4 weeks to 6 months (depending on the product used) prior study entry

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 0.25% DHEA (Type: EXPERIMENTAL): None
- 0.5% DHEA (Type: EXPERIMENTAL): None
- 1.0% DHEA (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).